Renalys Pharma Reports Promising Results from Phase III Study of Sparsentan for IgA Nephropathy in Japan Renalys Pharma revealed positive outcomes from a Phase III trial of sparsentan in Japanese IgA nephropathy patients, indicating a potential new treatment option in Japan.

Renalys Pharma Reports Promising Results from Phase III Study of Sparsentan for IgA Nephropathy in Japan #Japan #Tokyo #Sparsentan #Renalys_Pharma #IgA_nephropathy

Chugai Pharmaceutical Takes Significant Step by Acquiring Renalys Pharma Chugai Pharmaceutical has announced its strategic acquisition of Renalys Pharma, enhancing its capabilities in chronic kidney disease treatments across Asia.

Chugai Pharmaceutical Takes Significant Step by Acquiring Renalys Pharma #Japan #Tokyo #Sparsentan #Renalys_Pharma #Chugai_Pharmaceutical

Renalys Pharma Finalizes Agreement with Japan's PMDA for Clinical Trials of Sparsentan Renalys Pharma announces a key agreement with Japan's PMDA for Phase III trials of Sparsentan aimed at treating FSGS and Alport Syndrome, with a focus on enhancing kidney health.

Renalys Pharma Finalizes Agreement with Japan's PMDA for Clinical Trials of Sparsentan #Japan #Tokyo #Sparsentan #Renalys_Pharma #FSGS

Renalys Completes Data Collection for Sparsentan Phase III Trial in Japan Renalys announces the completion of primary endpoint data collection for its Phase III trial of Sparsentan for IgA nephropathy in Japan, marking a significant milestone in renal health.

Renalys Completes Data Collection for Sparsentan Phase III Trial in Japan #Japan #Tokyo #Sparsentan #IgA_nephropathy #Renalys

Acta Crystallographica Section C Structural Chemistry Acta Crystallographica Section C Structural Chemistry

September issue @actacrystc.iucr.org The cover article reports the complex disorder of sparsentan modelled using energy calculations #Innsbruck #Christian #Doppler #Laboratory #disorder #conformation #pharmaceutical #sparsentan #SST #openaccess #IUCr journals.iucr.org/c/issues/202...

NICE recommends sparsentan for IgA nephropathy - PharmaTimes First non-immunosuppressive dual-action therapy approved for eligible patients

#renalmedicine #CSLVifor #nephrology #sparsentan #FILSPARI #IgAnephropathy #nonimmunosuppressivedualactiontherapy #NICE #NHS #primaryIgAnephropathy #PROTECTcliicaltrial #NICEguidance #IgAnephropathypatients #primaryglomerulardisease #kidneyfailure #Proteinuria
pharmatimes.com/news/nice-re...

Graphic about NICE recommending a new treatment for primary IgA nephropathy (Berger's disease) to slow kidney damage, shared by Kidney Care UK. The image in the background shows someone holding a brown pill between their thumb and forefinger next to a pill box. There is a teal theme to the image. The Kidney Care UK logo is at the bottom right side.

1/3 📰 We are pleased to see the announcement from @nicecomms.bsky.social today about recommending medication #Sparsentan for treating primary IgA nephropathy (#IgAN), also known as #BergersDisease...

NICE Endorses Sparsentan as a Viable Treatment for IgA Nephropathy in England The National Institute for Health and Care Excellence has recommended Sparsentan, a dual-action therapy, for treating IgA nephropathy in England, offering hope to patients.

NICE Endorses Sparsentan as a Viable Treatment for IgA Nephropathy in England #United_Kingdom #England #Sparsentan #IgA_nephropathy #NICE

NICE Endorses FILSPARI® as a Key Treatment for IgA Nephropathy in England The recent NICE guidance endorses FILSPARI® (sparsentan) for treating IgA nephropathy, marking a significant advancement in kidney health options for patients in England.

NICE Endorses FILSPARI® as a Key Treatment for IgA Nephropathy in England #United_Kingdom #England #Sparsentan #FILSPARI #NICE

SPARTAN Trial Interim Results in Patients With IgAN | Docwire News Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgA nephropathy (IgAN).

Interim results of a trial of #sparsentan in #IgAN were presented at #NKFClinicals. #IgAnephropathy #nephrology #nephsky #kidney www.docwirenews.com/post/spartan...

SPARTAN Trial: Sparsentan Moves Up to First-Line in IgA Nephropathy Phase II study shows about a 70% reduction in proteinuria and hints at biomarkerdriven benefits

Interesting discussion!

@sagarnigs.bsky.social on @medpagetoday.bsky.social with Shikha Wadhwani and @edgarvlermamd.bsky.social

www.medpagetoday.com/meetingcover...

#Sparsentan in IgAN

#NephSky

🌟Beyond Testing—IgAN Trials Unveiled!-Must Read🌟

From #Sparsentan to #Iptacopan, innovative non-immunomodulatory & immunomodulatory therapies are transforming IgAN care!🎯

🔬 Excellent Trial insights by @Melgreux
📖 via @KidneyKolumns Jan25

#Nephrology #IgAN #ClinicalTrials

With sNDA, Travere Hopes to Expand Use of Sparsentan to FSGS | Docwire News Travere Therapeutics will submit a supplemental New Drug Application to the FDA requesting approval of sparsentan (Filspari) to treat focal segmental glomerulosclerosis (FSGS).

Travere will submit an sNDA requesting traditional approval of sparsentan (Filspari) for FSGS by the end of Q1 2025. #fsgs #sparsentan #kidneydisease #nephrology #nephsky

Renalys Pharma Completes Patient Enrollment for Sparsentan Clinical Trial in Japan Renalys Pharma has completed patient enrollment for the Phase III clinical trial of sparsentan, aimed at treating IgA nephropathy in Japan, aiming for timely patient care.

Renalys Pharma Completes Patient Enrollment for Sparsentan Clinical Trial in Japan #Japan #Tokyo #Sparsentan #Renalys_Pharma #IgA_nephropathy

Renalys Pharma's Sparsentan Secures Orphan Drug Status for IgA Nephropathy in Japan Renalys Pharma announces that Sparsentan has received Orphan Drug Designation in Japan for treating IgA nephropathy, a significant step towards addressing unmet medical needs.

Renalys Pharma's Sparsentan Secures Orphan Drug Status for IgA Nephropathy in Japan #Japan #Tokyo #Sparsentan #Renalys_Pharma #IgA_nephropathy